Published in Neuropsychiatr Dis Treat on July 11, 2016
Neurogenesis in the adult human hippocampus. Nat Med (1998) 17.53
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet (2004) 14.31
A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A (1996) 11.37
Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet (2006) 11.14
Subgenual prefrontal cortex abnormalities in mood disorders. Nature (1997) 9.36
The mGluR theory of fragile X mental retardation. Trends Neurosci (2004) 8.88
Potential therapeutic applications of autophagy. Nat Rev Drug Discov (2007) 8.56
Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem (2003) 6.84
Enhanced synaptic plasticity in newly generated granule cells of the adult hippocampus. Nature (2004) 6.15
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol (2001) 6.12
Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature (2011) 6.08
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol (2007) 5.78
Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2008) 5.37
Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell (2009) 5.34
A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain. Neuron (2007) 5.31
Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol (2005) 5.21
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Rethinking schizophrenia. Nature (2010) 4.85
Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron (2012) 4.31
Neural and developmental actions of lithium: a unifying hypothesis. Cell (1989) 4.13
Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol (2001) 4.00
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci (2007) 3.74
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60
Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry (2008) 3.28
Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry (2004) 3.23
LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron (2007) 3.17
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ (2013) 3.08
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord (2012) 3.01
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.91
Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord (2006) 2.74
Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry (2005) 2.64
Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol (2009) 2.60
Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol (2006) 2.57
Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci (2003) 2.54
Depression: a case of neuronal life and death? Biol Psychiatry (2004) 2.45
Unique processing during a period of high excitation/inhibition balance in adult-born neurons. Science (2012) 2.45
Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A (1999) 2.41
Lithium-induced increase in human brain grey matter. Lancet (2000) 2.31
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Enhancement of hippocampal neurogenesis by lithium. J Neurochem (2000) 2.28
Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry (2007) 2.27
Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A (2008) 2.23
Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry (2011) 2.20
The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci (2012) 2.16
Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol (2007) 2.15
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat Neurosci (2010) 2.08
Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol (2008) 2.08
The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem (1999) 2.04
Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology (2007) 2.02
Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci (2006) 2.01
BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry (2005) 2.00
The neuropathology and neurobiology of traumatic brain injury. Neuron (2012) 1.99
Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol (2009) 1.96
Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry (2007) 1.95
Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr (2008) 1.91
The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry (2007) 1.88
Reduced amygdalar gray matter volume in familial pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry (2005) 1.87
A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disord (2009) 1.83
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets (2006) 1.78
Increased BMP6 levels in the brains of Alzheimer's disease patients and APP transgenic mice are accompanied by impaired neurogenesis. J Neurosci (2010) 1.78
Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem (1999) 1.77
Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A (1998) 1.75
The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem (2001) 1.73
Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem (2002) 1.70
Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry (2009) 1.70
Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J (2004) 1.68
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2013) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A (2003) 1.62
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J Cereb Blood Flow Metab (2007) 1.60
Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) (2001) 1.60
Reliable activation of immature neurons in the adult hippocampus. PLoS One (2009) 1.60
Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Biol Psychiatry (2013) 1.59
Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry (2004) 1.55
Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem (2002) 1.55
Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry (2000) 1.55
Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry (2000) 1.53
Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res (2007) 1.53
Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med (2007) 1.52
Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport (1998) 1.52
Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry (2007) 1.52
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J Neurosci (2007) 1.48
Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem (2006) 1.48
GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One (2010) 1.47
Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disord (2009) 1.46
Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain (2009) 1.44
Traumatic brain injury: a risk factor for Alzheimer's disease. Neurosci Biobehav Rev (2012) 1.44
Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest (2012) 1.42
Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J (2009) 1.42
Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience (2008) 1.42
Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology (2007) 1.42
Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations. Autophagy (2006) 1.42
In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology (2004) 1.41
Improving Prognostic Accuracy in Subjects at Clinical High Risk for Psychosis: Systematic Review of Predictive Models and Meta-analytical Sequential Testing Simulation. Schizophr Bull (2017) 0.78
Onset polarity and illness course in bipolar I and II disorders: The predictive role of broadly defined mixed states. Compr Psychiatry (2015) 0.76
The adolescent emotional coping after an earthquake: a risk factor for suicidal ideation. J Adolesc (2014) 0.76
Treatment of bipolar depression. CNS Spectr (2013) 0.75
Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatr Dis Treat (2015) 0.75
Gender and occupational role differences in work-related post-traumatic stress symptoms, burnout and global functioning in emergency healthcare workers. Intensive Crit Care Nurs (2021) 0.75
Predictors of recurrence during long-term treatment of bipolar I and II disorders. A 4 year prospective naturalistic study. J Affect Disord (2017) 0.75
New DSM-5 PTSD guilt and shame symptoms among Italian earthquake survivors: Impact on maladaptive behaviors. Psychiatry Res (2016) 0.75
Three-Month Follow-up Study of Mental Health Outcomes After a National COVID-19 Lockdown: Comparing Patients With Mood or Anxiety Disorders Living in an Area With a Higher Versus Lower Infection Incidence. J Clin Psychiatry (2022) 0.75
Adult separation anxiety disorder in complicated grief: an exploratory study on frequency and correlates. Compr Psychiatry (2016) 0.75
Clinical correlates of plasma brain-derived neurotrophic factor in post-traumatic stress disorder spectrum after a natural disaster. Psychiatry Res (2016) 0.75